



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of **Francesca Chiodi**
Application No. **09/719,646**
Attorney Docket No. **0380-P02373US0**
Filed: **February 28, 2001**
For: **FAS PEPTIDES AND ANTIBODIES FOR
MODULATING APOPTOSIS**
Examiner: **A. M. Harris**
Group Art Unit: **1642**

CERTIFICATE OF MAILING UNDER 37 C.F.R § 1.8(a)

I hereby certify that this Correspondence is being deposited on the date identified below with the United States Postal Service as first-class mail in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-14500

2/5/04
Date of Certificate

Caren Burgoon
Caren Burgoon

Mail Stop:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

In accordance with the provisions of 37 C.F.R. § 1.56, Applicants hereby submit the attached Form PTO-1449 listing additional references which the Patent Examiner is requested to consider and make of record in the above-identified application. Copies of each of the listed references are enclosed herewith. This submission is believed to be in full compliance with the requirements of 37 CFR §§1.97 and 1.98. Accordingly, Applicants believe that no fee is required pursuant to 37 C.F.R. §1.97 (b) (3). In the event a fee is required, the Commissioner is authorized to charge the required fees to deposit account no. 04-1406. A duplicate copy of this sheet is included for fee processing.

In the opinion of the undersigned, the references submitted herewith, together with those previously submitted with the Information Disclosure Statement filed March 23, 2001, are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of this application.


The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with MPEP §609.

Early and favorable consideration of this application is respectfully requested.

Respectfully submitted,

DANN, DORFMAN, HERRELL & SKILLMAN
A Professional Corporation
Attorneys for Applicant(s)

By




Patrick J. Hagan
Registration No. 27,643

Telephone: (215) 563-4100

Facsimile: (215) 563-4044

Enclosures - Form PTO-1449

Copies of references listed on PTO - 1449



INFORMATION DISCLOSURE STATEMENT

SHEET 1 OF 2

Complete if known

Application Number: 09/719,646

Filing Date: February 28, 2001

First Named Inventor: Francesca Chiodi

Group Art Unit: 1642

Examiner Name: A. M. Harris

Attorney Docket Number: 0380-P02373US0

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	5,620,889	04-15-1997	Lynch et al.
	A2	5,830,469	11-03-1998	Lynch et al.
	A3	6,015,559	01-18-2000	Lynch et al.
	A4	5,891,434	04-06-1999	Krammer et al.
	A5	6,086,877	07-11-2000	Nishioka et al.
	A6	5,652,210	07-29-1997	Barr et al.
	A7	5,663,070	09-02-1997	Barr et al.
	A8	5,874,546	02-23-1999	Nagata et al.
	A9	6,270,998 B1	08-07-2001	Nagata et al.

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1	WO 95/10540	PCT	04-20-1995	Immunex Corporation
	B2	EP 0 799 891 A1	EP	10-08-1997	Sankyo Company Limited
	B3	EP 0 990 663 A2	EP	04-05-2000	Sankyo Company Limited
	B4	WO 97/12632	PCT	04-10-1997	TKB Associates Limited Partnership
	B5	EP 0 709 097 A1	EP	05-01-1996	Santen Pharmaceutical Co., Ltd.
	B6	EP 0 510 691 A1	EP	10-28-1992	OSAKA BIOSCIENCE INSTITUTE
	B7	EP 0 511 202 B1	EP	11-04-1992	Krammer, Peter H.
	B8	EP 1180369 A1	EP	02-20-2002	Sankyo Company, Liimited

EXAMINER'S SIGNATURE		DATE CONSIDERED	
----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**



SHEET 2 OF 2

Complete if known

Application Number: 09/719,646

Filing Date: February 28, 2001

First Named Inventor: Francesca Chiodi

Group Art Unit: 1642

Examiner Name: A. M. Harris

Attorney Docket Number: 0380-P02373US0

OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	Stricker, K., et al., "Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus Type 1 (HIV-1)-infected children", Cell Death and Differentiation, 5: 222-230, (1998).

EXAMINER'S SIGNATURE	DATE CONSIDERED
----------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.